This indicates not only the complex contribution of sirtuins to aneurysm pathobiology as a whole but may also complicate pharmacological treatment, particularly with regard to the use of pharmacological SIRT1 agonists [289] versus use of SIRT1 antagonists [212] for AA treatment. Here, SIRT1 is linked to aneurysm.